Literature DB >> 25824247

Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample.

Elena Libhaber1, Angela J Woodiwiss2, Andrew Raymond1, Monica Gomes1, Muzi J Maseko1, Pinhas Sareli1, Gavin R Norton1.   

Abstract

Although the profibrotic inflammatory substance galectin-3 predicts outcomes in the general population, the mechanisms responsible for this effect are uncertain. We aimed to determine whether circulating galectin-3 concentrations are associated with carotid femoral (aortic) pulse wave velocity and aortic reflective wave index (applanation tonometry and SphygmoCor software) in 966 randomly selected participants from a community sample. Galectin-3 concentrations were not independently associated with office (n=966) or 24-hour (n=661) systolic (P=0.88-0.92) or diastolic (P=0.65-0.94) blood pressure. In contrast, with adjustments for age, sex (in all participants), office or 24-hour mean arterial pressure (or systolic blood pressure and pulse pressure), pulse rate, body mass index, regular smoking, regular alcohol intake, total cholesterol concentrations, diabetes mellitus or an glycohemoglobin >6.1%, treatment for hypertension, and estimated glomerular filtration rate, galectin-3 was independently associated with aortic pulse wave velocity in all participants (partial r=0.15, P<0.0001) and reflective wave index in men (partial r=0.13, P<0.02). In 745 participants who had never received antihypertensive therapy, galectin-3 concentrations were similarly independently associated with pulse wave velocity in all participants (partial=0.16, P<0.0001) and reflective wave index in men (partial r=0.15, P<0.02). The blood pressure-independent relations between galectin-3 concentrations and aortic hemodynamics persisted with further adjustments for C-reactive protein concentrations (pulse wave velocity in all participants: partial r=0.14, P<0.0001; reflective wave index in men: partial r=0.12, P<0.05). In conclusion, despite a lack of independent association with brachial blood pressure, the profibrotic inflammatory substance galectin-3 may contribute toward adverse outcomes through an effect on aortic stiffness, an effect that cannot be attributed to general inflammatory changes.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  aortic stiffness; blood pressure; galectin-3

Mesh:

Substances:

Year:  2015        PMID: 25824247     DOI: 10.1161/HYPERTENSIONAHA.115.05159

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Disease severity impacts the relationship of apelin with arterial function in patients with rheumatoid arthritis.

Authors:  Sulé Gunter; Chanel Robinson; Gavin R Norton; Angela J Woodiwiss; Linda Tsang; Aletta M E Millen; Patrick H Dessein
Journal:  Clin Rheumatol       Date:  2018-02-08       Impact factor: 2.980

2.  Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index.

Authors:  Ana I Casanegra; Julie A Stoner; Alfonso J Tafur; H Anne Pereira; Suman W Rathbun; Andrew W Gardner
Journal:  Vasc Med       Date:  2016-05-07       Impact factor: 3.239

3.  Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis.

Authors:  Panagiota Anyfanti; Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Panagiotis Dolgyras; Vasiliki Galanopoulou; Spyros Aslanidis; Stella Douma
Journal:  Clin Cardiol       Date:  2018-11-27       Impact factor: 2.882

4.  Galectin-3 and Hypertensive Heart Disease.

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-23       Impact factor: 3.738

5.  Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model.

Authors:  Jaime Ibarrola; Ernesto Martínez-Martínez; J Rafael Sádaba; Vanessa Arrieta; Amaia García-Peña; Virginia Álvarez; Amaya Fernández-Celis; Alicia Gainza; Patrick Rossignol; Victoria Cachofeiro Ramos; Natalia López-Andrés
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923

6.  Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment.

Authors:  Beata Bobrowska; Ewa Wieczorek-Surdacka; Olga Kruszelnicka; Bernadeta Chyrchel; Andrzej Surdacki; Dariusz Dudek
Journal:  Int J Mol Sci       Date:  2017-04-29       Impact factor: 5.923

7.  Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.

Authors:  My-Nhan Nguyen; Yidan Su; Donna Vizi; Lu Fang; Andris H Ellims; Wei-Bo Zhao; Helen Kiriazis; Xiao-Ming Gao; Junichi Sadoshima; Andrew J Taylor; Julie R McMullen; Anthony M Dart; David M Kaye; Xiao-Jun Du
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

8.  Association between circulating Galectin-3 and arterial stiffness in older adults.

Authors:  Xiaoming Jia; Caroline Sun; Hirofumi Tanaka; Mahmoud Al Rifai; David Aguilar; Chiadi Ndumele; Elizabeth Selvin; Salim S Virani; Ron C Hoogeveen; Gerardo Heiss; Christie M Ballantyne; Vijay Nambi
Journal:  Vasa       Date:  2021-08-04       Impact factor: 1.961

Review 9.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel
Journal:  J Am Heart Assoc       Date:  2016-01-25       Impact factor: 5.501

10.  Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?

Authors:  Radu Ioan Lala; Dan Darabantiu; Luminita Pilat; Maria Puschita
Journal:  Arq Bras Cardiol       Date:  2016-01-12       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.